Search Results

Cogent Biosciences, Inc., a biotechnology company focused on developing precision therapies for genetically defined diseases, announced the appointment of Cole Pinnow as Chief Commercial Officer.

Cogent Biosciences, Inc., a biotechnology company focused on developing precision therapies for genetically defined diseases, provided a business update and announced financial results for the first quarter ended March 31, 2024.

Cogent Biosciences, Inc. announced it has reached alignment with the U.S. Food and Drug Administration on the Company’s novel patient reported outcome measure, Mastocytosis Symptom Severity Daily Diary, for use in Part 2 of the registration-directed SUMMIT trial evaluating bezuclastinib in Nonadvanced Systemic Mastocytosis patients.

Cogent Biosciences, Inc. announced additional data from Part 1 of its ongoing SUMMIT clinical trial evaluating the selective KIT D816V inhibitor, bezuclastinib, in patients with nonadvanced systemic mastocytosis.

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results.

Cogent Biosciences, Inc. announced it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $225 million to the Company, before deducting placement agent fees and offering expenses.

Cogent Biosciences, Inc. announced positive updated lead-in data from the company’s ongoing Phase 3 PEAK trial evaluating the selective and potent KIT mutant inhibitor, bezuclastinib, in combination with sunitinib, in patients with Gastrointestinal Stromal Tumors.